Berkshire Asset Management’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$82.8M Buy
380,870
+3,922
+1% +$870K 3.55% 2
2025
Q4
$86.1M Sell
376,948
-3,451
-0.9% -$786K 3.78% 3
2025
Q3
$88.1M Sell
380,399
-3,428
-0.9% -$698K 3.74% 3
2025
Q2
$71.2M Buy
383,827
+205
+0.1% +$38.1K 3.23% 3
2025
Q1
$71.2M Sell
383,622
-4,335
-1% -$843K 3.41% 3
2024
Q4
$66.1M Sell
387,957
-17,757
-4% -$3.26M 3.12% 3
2024
Q3
$69.6M Hold
405,714
3.54% 3
2024
Q2
$69.6M Buy
405,714
+17,404
+4% +$2.88M 3.47% 3
2024
Q1
$70.7M Sell
388,310
-3,429
-0.9% -$591K 3.74% 3
2023
Q4
$60.7M Sell
391,739
-429
-0.1% -$62.5K 3.46% 3
2023
Q3
$58.5M Sell
392,168
-2,822
-0.7% -$414K 3.65% 4
2023
Q2
$53.2M Buy
394,990
+8,101
+2% +$1.19M 3.16% 6
2023
Q1
$61.7M Sell
386,889
-2,427
-0.6% -$371K 3.81% 2
2022
Q4
$62.9M Buy
389,316
+2,600
+0.7% +$399K 4.04% 2
2022
Q3
$51.9M Sell
386,716
-5,111
-1% -$733K 3.67% 2
2022
Q2
$60M Buy
391,827
+6,893
+2% +$1.05M 3.92% 1
2022
Q1
$62.4M Buy
384,934
+3,722
+1% +$541K 3.94% 2
2021
Q4
$51.6M Sell
381,212
-1,955
-0.5% -$231K 3.14% 4
2021
Q3
$41.3M Buy
383,167
+8,343
+2% +$953K 2.77% 6
2021
Q2
$42.2M Buy
374,824
+15,501
+4% +$1.75M 2.85% 5
2021
Q1
$38.9M Sell
359,323
-13,484
-4% -$1.44M 2.88% 6
2020
Q4
$39.9M Buy
372,807
+32,702
+10% +$3.14M 3.07% 4
2020
Q3
$29.8M Sell
340,105
-25,853
-7% -$2.43M 2.88% 6
2020
Q2
$35.9M Buy
365,958
+12,013
+3% +$1.06M 3.31% 5
2020
Q1
$27M Buy
353,945
+8,298
+2% +$707K 2.81% 6
2019
Q4
$30.6M Sell
345,647
-8,033
-2% -$667K 2.6% 8
2019
Q3
$26.8M Sell
353,680
-17,191
-5% -$1.18M 2.31% 9
2019
Q2
$27M Buy
370,871
+23,732
+7% +$1.87M 2.23% 9
2019
Q1
$28M Buy
347,139
+385
+0.1% +$31.5K 2.37% 6
2018
Q4
$32M Sell
346,754
-292
-0.1% -$25.7K 2.99% 4
2018
Q3
$32.8M Buy
347,046
+15,748
+5% +$1.49M 2.78% 3
2018
Q2
$30.7M Buy
331,298
+3,165
+1% +$309K 2.88% 4
2018
Q1
$31.1M Buy
328,133
+2,983
+0.9% +$328K 3.02% 4
2017
Q4
$31.4M Buy
325,150
+26,126
+9% +$2.46M 3.05% 4
2017
Q3
$26.6M Sell
299,024
-2,212
-0.7% -$168K 2.96% 3
2017
Q2
$21.8M Buy
301,236
+3,431
+1% +$231K 2.49% 8
2017
Q1
$19.4M Buy
297,805
+11,135
+4% +$700K 2.3% 10
2016
Q4
$18M Buy
286,670
+18,913
+7% +$1.15M 2.32% 14
2016
Q3
$16.9M Buy
267,757
+9,295
+4% +$602K 2.43% 11
2016
Q2
$16M Sell
258,462
-11,856
-4% -$722K 2.43% 12
2016
Q1
$15.4M Buy
270,318
+6,959
+3% +$388K 2.4% 13
2015
Q4
$15.6M Buy
263,359
+14,894
+6% +$858K 2.58% 11
2015
Q3
$13.5M Buy
248,465
+5,686
+2% +$370K 2.41% 12
2015
Q2
$16.3M Sell
242,779
-402
-0.2% -$26.2K 2.74% 8
2015
Q1
$14.2M Buy
243,181
+3,946
+2% +$238K 2.38% 11
2014
Q4
$15.7M Buy
239,235
+6,510
+3% +$410K 2.69% 6
2014
Q3
$13.4M Sell
232,725
-651
-0.3% -$36.1K 2.48% 9
2014
Q2
$13.2M Sell
233,376
-9,402
-4% -$493K 2.45% 9
2014
Q1
$12.5M Sell
242,778
-6,565
-3% -$332K 2.4% 9
2013
Q4
$13.2M Buy
249,343
+31,453
+14% +$1.55M 2.48% 8
2013
Q3
$9.75M Buy
217,890
+16,512
+8% +$732K 2.34% 12
2013
Q2
$8.32M Buy
+201,378
New +$8.81M 2.3% 14

Other funds holding ABBV

Berkshire Asset Management's ABBV Position: Q1 2026 in Review

Berkshire Asset Management increased its AbbVie (ABBV) stake by 1% in Q1 2026, buying an estimated $870K and bringing the position to 380,870 shares worth $82.8M. The position accounts for 3.55% of the portfolio, ranked #2.

Berkshire Asset Management first reported a position in ABBV in Q2 2013 and has held it in 52 quarters since. The position peaked at $88.1M in Q3 2025. 4,077 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Berkshire Asset Management held 380,870 shares of AbbVie worth $82.8M as of Q1 2026.
  • Berkshire Asset Management bought 3,922 AbbVie shares in Q1 2026, an estimated $870K.
  • AbbVie made up 3.55% of Berkshire Asset Management's portfolio in Q1 2026, its #2 holding.
  • Berkshire Asset Management first reported a position in AbbVie in Q2 2013 and has held it in 52 quarters since.
  • Berkshire Asset Management's AbbVie position peaked at $88.1M in Q3 2025.
  • 4,077 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Berkshire Asset Management's 13F filing for Q1 2026, filed 11 May 2026.